1. Psychoneuroendocrinology
Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial 
Marie Bixo, Karin Ekberg, Inger Sundström Poromaa, Angelica Lindén Hirschberg, Aino Fianu Jonasson, Lotta Andréen, Erika Timby, Marianne Wulff, Agneta Ehrenborg, Torbjörn Bäckström 
Psychoneuroendocrinology 
Volume 80, Pages (June 2017)
DOI: /j.psyneuen
Copyright © 2017 The Authors Terms and Conditions

2. Fig. 1 The flow of patients through the study part 2.
Psychoneuroendocrinology  , 46-55DOI: ( /j.psyneuen )
Copyright © 2017 The Authors Terms and Conditions

3. Fig. 2
Total DRSP score at baseline (minimal value=21) men±SEM during 2 diagnostic cycles for (A) the group subsequently randomized to active treatment with UC1010 compared to the group randomized to placebo (n=106) and (B) in subjects with pure PMDD and the subject with premenstrual exacerbation of symptoms.
Psychoneuroendocrinology  , 46-55DOI: ( /j.psyneuen )
Copyright © 2017 The Authors Terms and Conditions

4. Fig. 3
Reduction of Total DRSP score (top panel) and Negative mood score (bottom panel) in the group treated with UC1010 compared to placebo (PP population, n=106). Mean reduction in ratings (±SEM) and% change from baseline are shown.
Psychoneuroendocrinology  , 46-55DOI: ( /j.psyneuen )
Copyright © 2017 The Authors Terms and Conditions

5. Fig. 4
Reduction of Total DRSP score (top panel), Negative mood score (middle panel) and impairment (bottom panel) in a sub-group with pure PMDD treated with UC1010 compared to placebo during the symptomatic luteal phase (n=60). Mean reduction in ratings (±SEM) and% change from baseline are shown.
Psychoneuroendocrinology  , 46-55DOI: ( /j.psyneuen )
Copyright © 2017 The Authors Terms and Conditions